Federal Register / Vol. 82, No. 220 / Thursday, November 16, 2017 / Notices 53513 

Serial Number PCT/US2013/050688, 

filed 07/16/2013; HHS Reference No. E– 

162–2013/0–US–03, United States 

Patent Application Serial Number 13/ 

943,430, filed 07/16/2013; HHS 

Reference No. E–162–2013/0–EP–04, 

European Patent Application Serial 

Number 13819718.1, filed 02/05/2015; 

and HHS Reference No. E–162–2013/0– 

JP–05, Japanese Patent Application 

Serial Number 2015–523183, filed 01/ 

08/2015. All rights in these inventions 

have been assigned to the Government 

of the United States of America. 

The prospective exclusive patent 

commercialization license territory may 

be worldwide and the field of use may 

be limited to: ‘‘Use of the licensed 

patent rights for the development, 

manufacture, and sale of a lateral flow 

device for detection of antineoplastic 

drugs from surfaces’’. 

Many types of cancers are treated 

with antineoplastic drugs, also known 

as anti-cancer drugs or chemotherapy. 

Exposure of healthcare workers to these 

hazardous drugs from contaminated 

surfaces may cause acute and long-term 

effects. Approximately eight (8) million 

United States healthcare workers are 

potentially exposed to these hazardous 

drugs. Although there are potential 

therapeutic benefits of hazardous drugs 

that outweigh the risks of side effects for 

ill patients, healthcare workers are 

exposed to the risk with the same side 

effects with no therapeutic benefit. 

Occupational exposures to hazardous 

drugs can lead to skin rashes and major 

reproductive effects, which include 

increased fetal loss, congenital 

malformations, low birth weight, 

congenital abnormalities, and infertility. 

The risk of cancer is also increased after 

exposure to these drugs. 

This invention, developed within the 

National Institute for Occupational 

Safety and Health at the Centers for 

Disease Control and Prevention, 

describes a lateral flow assay-based 

antineoplastic drug detection method 

that utilizes antibodies specific for 

individual drugs. It uses detectors for 

the assessment of drug residues on 

surfaces, which can be incorporated into 

small, portable drug detection devices 

that allow healthcare workers to sample 

surfaces in near real time, avoiding the 

need to take samples back to the 

laboratory to be tested. 

This notice is made in accordance 

with 35 U.S.C. 209 and 37 CFR part 404. 

The prospective exclusive patent 

commercialization license will be 

royalty bearing and may be granted 

unless within fifteen (15) days from the 

date of this published notice, the 

National Institute of Allergy and 

Infectious Diseases receives written 

evidence and argument that establishes 

that the grant of the license would not 

be consistent with the requirements of 

35 U.S.C. 209 and 37 CFR part 404. 

Complete applications for a license in 

the prospective field of use that are 

timely filed in response to this notice 

will be treated as objections to the grant 

of the contemplated exclusive patent 

commercialization license. Comments 

and objections submitted in response to 

this notice will not be made available 

for public inspection and, to the extent 

permitted by law, will not be released 

under the Freedom of Information Act, 

5 U.S.C. 552. 

Dated: November 9, 2017. 

Suzanne Frisbie, 

Deputy Director, Technology Transfer and 

Intellectual Property Office, National Institute 

of Allergy and Infectious Diseases. 

[FR Doc. 2017–24774 Filed 11–15–17; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Eye Institute; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of a 

meeting of the Board of Scientific 

Counselors, National Eye Institute. 

The meeting will be closed to the 

public as indicated below in accordance 

with the provisions set forth in section 

552b(c)(6), Title 5 U.S.C., as amended 

for the review, discussion, and 

evaluation of individual grant 

applications conducted by the 

NATIONAL EYE INSTITUTE, including 

consideration of personnel 

qualifications and performance, and the 

competence of individual investigators, 

the disclosure of which would 

constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Board of Scientific 

Counselors, National Eye Institute. 

Date: December 3–5, 2017. 

Time: 6:00 p.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Building 31, Conference Room 6C6, 31 

Center Drive, Bethesda, MD 20892. 

Contact Person: Sheldon S. Miller, Ph.D., 

Scientific Director, National Institutes of 

Health, National Eye Institute, Bethesda, MD 

20892, (301) 451–6763. 

Information is also available on the 

Institute’s/Center’s home page: 

www.nei.nih.gov, where an agenda and any 

additional information for the meeting will 

be posted when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.867, Vision Research, 

National Institutes of Health, HHS) 

Dated: November 9, 2017. 

Natasha M. Copeland, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2017–24760 Filed 11–15–17; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HOMELAND 

SECURITY 

Federal Emergency Management 

Agency 

[Internal Agency Docket No. FEMA–4344– 

DR; Docket ID FEMA–2017–0001] 

California; Amendment No. 5 to Notice 

of a Major Disaster Declaration 

AGENCY: Federal Emergency 

Management Agency, DHS. 

ACTION: Notice. 

SUMMARY: This notice amends the notice 

of a major disaster declaration for the 

State of California (FEMA–4344–DR), 

dated October 10, 2017, and related 

determinations. 

DATES: This amendment was issued 

November 7, 2017. 

FOR FURTHER INFORMATION CONTACT: 

Dean Webster, Office of Response and 

Recovery, Federal Emergency 

Management Agency, 500 C Street SW., 

Washington, DC 20472, (202) 646–2833. 

SUPPLEMENTARY INFORMATION: Notice is 

hereby given that the incident period for 

this disaster is closed effective October 

31, 2017. 

The following Catalog of Federal Domestic 

Assistance Numbers (CFDA) are to be used 

for reporting and drawing funds: 97.030, 

Community Disaster Loans; 97.031, Cora 

Brown Fund; 97.032, Crisis Counseling; 

97.033, Disaster Legal Services; 97.034, 

Disaster Unemployment Assistance (DUA); 

97.046, Fire Management Assistance Grant; 

97.048, Disaster Housing Assistance to 

Individuals and Households In Presidentially 

Declared Disaster Areas; 97.049, 

Presidentially Declared Disaster Assistance— 

Disaster Housing Operations for Individuals 

and Households; 97.050 Presidentially 

Declared Disaster Assistance to Individuals 

and Households—Other Needs; 97.036, 

Disaster Grants—Public Assistance 

(Presidentially Declared Disasters); 97.039, 

Hazard Mitigation Grant. 

Brock Long, 

Administrator, Federal Emergency 

Management Agency. 

[FR Doc. 2017–24910 Filed 11–15–17; 8:45 am] 

BILLING CODE 9111–23–P 


asabaliauskas on DSKBBXCHB2PROD with NOTICES